Igniting Biotech Innovation in Neurodegenerative Disorders

It is widely recognized that neurodegenerative disorders represent one of the most challenging areas for new drug development. These diseases have devastating human cost on the lives of patients and families, as well as a burden on healthcare systems and society. For example, the cost to society of Alzheimer ’s disease is estimated to skyrocket to $1 trillion annually in the U.S. by the year 2050.In spite of the challenges, research and drug development in neuroscience and neurodegenerative diseases is pushing new frontiers. The prospect of real breakthroughs is on the horizon. If we imagine the possibilities that the current progress in biotechnology innovation will yield by the year 2050, we can envision that there will be new life-changing medicines for these devastating diseases of the brain, currently with very limited treatment options for patients: Alzheimer ’s, ALS, Huntington’s, Parkinson’s diseases. I believe we are on the cusp of advancing new medicines for neurodegenerative disorders to millions of patients in need. Let me predict some of the progress that will be made in Alzheimer ’s disease, which is the key therapeutic focus for my company, Alzheon.Biotech companies will play a role in bringing approved medicines to Alzheimer ’s patients. Biotech companies have already emerged in the land of the ‘giants’ of the big pharmaceutical companies who have traditionally carried out Alzheimer’s drug development. ...
Source: ePharma Summit - Category: Pharmaceuticals Tags: #PSANYC16 alzheimers disease alzheimers drug development biotech companies biotech innovation neurodegenerative disorders Pharmaceutical Strategy Conference Source Type: blogs